Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High at $5.40
Compass Therapeutics (NASDAQ:CMPX) Hits New 52-Week High at $5.40
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) reached a new 52-week high on Thursday . The stock traded as high as $5.40 and last traded at $5.14, with a volume of 20745 shares. The stock had previously closed at $4.79.
指南针治疗公司(纳斯达克：cmpx-get评级)周四创下52周新高。该股盘中一度涨至5.4美元，最新报5.14美元，成交量为20745股。该股此前收盘价为4.79美元。
Analyst Ratings Changes
分析师评级发生变化
Several equities research analysts have weighed in on CMPX shares. Raymond James upped their target price on Compass Therapeutics from $5.00 to $8.00 and gave the stock an "outperform" rating in a research note on Thursday, November 10th. EF Hutton Acquisition Co. I started coverage on Compass Therapeutics in a research note on Friday, December 16th. They set a "buy" rating and a $10.30 target price for the company. HC Wainwright cut their target price on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a research note on Thursday, November 3rd. Finally, LADENBURG THALM/SH SH upped their target price on Compass Therapeutics to $9.00 in a research note on Wednesday, November 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $9.46.
几位股票研究分析师加入了对CMPX股票的追捧。雷蒙德·詹姆斯在11月10日(星期四)的一份研究报告中将Compass Treateutics的目标价从5.00美元上调至8.00美元，并给予该股“跑赢大盘”的评级。EF Hutton Acquisition Co.I在12月16日星期五的一份研究报告中开始报道Compass治疗公司。他们为该公司设定了“买入”评级和10.30美元的目标价。11月3日星期四，HC Wainwright在一份研究报告中将Compass Treateutics的目标价从12.00美元下调至10.00美元，并为该公司设定了“买入”评级。最后，拉登堡THALM/SH SH在11月16日星期三的一份研究报告中将他们对Compass治疗公司的目标价格上调至9.00美元。根据MarketBeat.com的数据，五位股票研究分析师对该股的评级为买入，该公司的平均评级为“买入”，共识目标价为9.46美元。
Compass Therapeutics Stock Performance
Compass Treateutics股票表现
The firm's fifty day moving average price is $4.00 and its 200-day moving average price is $3.18.
该公司的50日移动均线价格为4.00美元，200日移动均线价格为3.18美元。
Insider Transactions at Compass Therapeutics
罗盘治疗公司的内幕交易
In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Thomas J. Schuetz acquired 15,000 shares of the firm's stock in a transaction that occurred on Monday, September 26th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $34,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,421,873 shares of the company's stock, valued at approximately $12,307,651.71. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Orbimed Advisors Llc acquired 402,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 8th. The stock was bought at an average price of $3.21 per share, with a total value of $1,290,420.00. Following the completion of the acquisition, the director now directly owns 15,219,994 shares of the company's stock, valued at $48,856,180.74. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 427,000 shares of company stock worth $1,347,670. Corporate insiders own 29.80% of the company's stock.
在相关新闻中，首席执行官托马斯·J·舒茨在9月26日星期一的一次交易中收购了该公司15,000股股票。收购股票的平均成本为每股2.27美元，交易总额为34,050.00美元。收购完成后，首席执行官现在直接拥有5,421,873股公司股票，价值约12,307,651.71美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。在相关新闻中，首席执行官托马斯·J·舒茨在9月26日星期一的一次交易中收购了该公司15,000股股票。收购股票的平均成本为每股2.27美元，交易总额为34,050.00美元。收购完成后，首席执行官现在直接拥有5,421,873股公司股票，价值约12,307,651.71美元。此次收购是在提交给美国证券交易委员会的一份文件中披露的，该文件可在这个环节。此外，董事在11月8日星期二的一次交易中收购了402,000股该公司的股票。这只股票是以每股3.21美元的平均价格购买的，总价值为1290,420.00美元。收购完成后，董事现在直接拥有15,219,994股公司股票，价值48,856,180.74美元。关于这次购买的披露可以找到这里。在过去的90天里，内部人士购买了427,000股公司股票，价值1,347,670美元。公司内部人士持有该公司29.80%的股份。
Institutional Trading of Compass Therapeutics
指南针治疗公司的机构交易
A number of large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Compass Therapeutics by 58.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,380,623 shares of the company's stock worth $5,428,000 after acquiring an additional 878,650 shares during the period. Eventide Asset Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $2,509,000. BlackRock Inc. boosted its position in shares of Compass Therapeutics by 433.9% during the 3rd quarter. BlackRock Inc. now owns 872,497 shares of the company's stock worth $1,989,000 after purchasing an additional 709,071 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Compass Therapeutics during the 3rd quarter worth about $598,000. Finally, Renaissance Technologies LLC boosted its position in shares of Compass Therapeutics by 397.5% during the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock worth $175,000 after purchasing an additional 52,865 shares in the last quarter. 54.27% of the stock is currently owned by institutional investors and hedge funds.
一些大型投资者最近买卖了该公司的股票。先锋集团在第三季度增持了58.5%的Compass Treateutics股份。先锋集团在此期间增持了878,650股，目前持有2,380,623股该公司股票，价值5,428,000美元。Evende Asset Management LLC在第三季度购买了Compass治疗公司股票的新头寸，价值约2,509,000美元。贝莱德股份有限公司在第三季度将其在罗盘治疗公司的股票持仓增加了433.9%。贝莱德股份有限公司在上个季度增持了709,071股后，现在持有872,497股该公司股票，价值1,989,000美元。SilverarcCapital Management LLC在第三季度购买了Compass治疗公司股票的新头寸，价值约598,000美元。最后，复兴科技有限责任公司在第二季度将其在Compass治疗公司的股票持有量增加了397.5%。复兴科技有限责任公司现在拥有66,165股该公司股票，价值17.5万美元，上个季度又购买了52,865股。54.27%的股票目前由机构投资者和对冲基金持有。
About Compass Therapeutics
关于指南针治疗公司
(Get Rating)
(获取评级)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.
Compass治疗公司是一家专注于临床阶段肿瘤学的生物制药公司，致力于开发基于抗体的疗法来治疗各种人类疾病。该公司处于临床开发阶段的候选产品包括CTX-009和CTX-471，CTX-009是一种研究中的双特异性抗体，可以阻断对血管生成和肿瘤血管形成至关重要的Delta-like配体4/Notch和血管内皮生长因子A信号通路；以及CTX-471，是CD137的激动剂，是一种IgG4单抗。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Lucid Motors Faces a Reality That May Cloud a Bullish Perception
- Institutions Put Bottom In Rite Aid Shares
- Here's Why You Should Steer Clear of the FedEx Bounce
- Why Did Viking Therapeutics Stock Skyrocket
- NIKE, Inc Swooshes Higher On Results And Outlook
- 免费获取StockNews.com关于指南针治疗的研究报告(CMPX)
- Lucid Motors面临的现实可能会给看涨的看法蒙上阴影
- 机构将Rite Aid的股票跌至谷底
- 这就是为什么你应该避开联邦快递的反弹
- 维京治疗公司股票为何暴涨
- 耐克公司业绩和前景走高
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《指南针治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Compass Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。